Futu News reported on April 9 that some anti-epidemic concept stocks were higher intraday. As of press release, Moderna had risen more than 5%, BioNTech had risen nearly 4%, Pfizer and Novavax Pharmaceuticals had risen nearly 2%, and NNVC, AstraZeneca, and HTBX had risen slightly.

According to media reports, the EU is seeking a new vaccine supply agreement with Pfizer to provide 1.8 billion doses of the vaccine from 2022 to 2023.

Also, researchers are about to try to develop an HIV vaccine using the latest mRNA (messenger ribonucleic acid) technology platform. Phase 1 clinical data showed that the vaccine had shown effectiveness against HIV. By the end of this year, new HIV vaccine trials will be conducted based on Moderna's mRNA platform.